{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:22:24Z","timestamp":1792232544594,"version":"4.4.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To integrate pharmacovigilance and network toxicology methods to explore the potential adverse drug events (ADEs) and toxic mechanisms of selumetinib, and to provide a reference for quickly understanding the safety and toxicological mechanisms of newly marketed drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Taking selumetinib as an example, this study integrated pharmacovigilance methods based on real-world data and network toxicology methods to analyze its ADE and its potential toxicological mechanism. First, the ADE reports of selumetinib were extracted from the US Food and Drug Administration (FDA) adverse event reporting system (FAERS), and the ADE signals were detected by reporting odds ratio (ROR) and UK medicines and healthcare products regulatory agency (MHRA) methods. The ADE signals were classified and described according to the preferred terms (PTs) and system organ class (SOC) derived from the Medical Dictionary for Regulatory Activities (MedDRA). The network toxicology method was used to analyze the toxicological mechanism of the interested SOCs. The specific steps included predicting the potential targets of selumetinib using TOXRIC, STITCH, ChEMBL, CTD, SwissTargetPreditcion, and Super-PRED databases, collecting the targets of SOC using GeneCards database, conducting protein-protein interaction (PPI) analysis through STRING database, conducting gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) analysis through DAVID database, and testing the molecular affinity using AutoDock software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1388 ADE reports related to selumetinib were extracted, and 53 positive signals were detected by ROR and MHRA methods, of which 20 signals were not mentioned in the package insert, including ingrowing nail, hyperphosphatemia, cardiac valve disease, hematuria, neutropenia, etc. Analysis of the toxicological mechanism of six SOCs involved in positive ADE signals revealed that the key targets included EGFR, STAT3, AKT1, IL6, BCL2, etc., and the key pathways included PI3K\/Akt pathway, apoptosis, ErbB signaling pathway, and EGFR tyrosine kinase inhibitor resistance, etc. Molecular docking assays showed spontaneous binding of selumetinib to key targets in these pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The pharmacovigilance analysis identified some new potential ADEs of selumetinib, and the network toxicology analysis showed that the toxic effects of selumetinib may be related to PI3K\/Akt pathway, apoptosis, ErbB signaling pathway, EGFR tyrosine kinase inhibitor resistance and other pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1432759","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T20:02:50Z","timestamp":1723752170000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficient analysis of adverse drug events and toxicological mechanisms of newly marketed drugs by integrating pharmacovigilance and network toxicology: selumetinib as an example"],"prefix":"10.3389","volume":"15","author":[{"given":"Rui","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengxu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1177\/10600280211046298","article-title":"A review of selumetinib in the treatment of neurofibromatosis type 1\u2013related plexiform neurofibromas","volume":"56","author":"Anderson","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"109761","DOI":"10.1016\/j.abb.2023.109761","article-title":"Identification of potential inhibitors against E.coli via novel approaches based on deep learning and quantum mechanics-based atomistic investigations","volume":"747","author":"Aziz","year":"","journal-title":"Arch. Biochem. Biophys."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0292455","DOI":"10.1371\/journal.pone.0292455","article-title":"Evaluation of anticancer potential of tetracene-5,12-dione (A01) and pyrimidine-2,4-dione (A02) via caspase 3 and lactate dehydrogenase cytotoxicity investigations","volume":"18","author":"Aziz","year":"","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1053\/j.ackd.2021.09.007","volume":"28","author":"Barbar","year":"2021","journal-title":"Adv. Chronic Kidney Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.2217\/fon-2018-0187","article-title":"Management and grading of EGFR inhibitor-induced cutaneous toxicity","volume":"14","author":"Beech","year":"2018","journal-title":"Future Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41416-023-02221-1","article-title":"The emerging role of PI3K inhibitors for solid tumour treatment and beyond","volume":"128","author":"Belli","year":"2023","journal-title":"Br. J. Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"OpenVigil\u2014free eyeballs on AERS pharmacovigilance data","volume":"30","author":"B\u00f6hm","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3390\/jcm13061792","article-title":"Dermatologic effects of selumetinib in pediatric patients with neurofibromatosis type 1: clinical challenges and therapeutic management","volume":"13","author":"Borgia","year":"2024","journal-title":"J. Clin. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40272-022-00551-w","article-title":"Characterization of cardiac function by echocardiographic global longitudinal strain in a cohort of children with neurofibromatosis type 1 treated with selumetinib","volume":"25","author":"Caiffa","year":"2022","journal-title":"Pediatr. Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1158\/1078-0432.CCR-20-5032","article-title":"FDA approval summary: selumetinib for plexiform neurofibroma","volume":"27","author":"Casey","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/13607863.2019.1594158","article-title":"Examining the relationship between changes in personality and depression in older adult cancer survivors","volume":"24","author":"Chow","year":"2020","journal-title":"Aging Ment. Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","article-title":"SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules","volume":"47","author":"Daina","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"D1257","DOI":"10.1093\/nar\/gkac833","article-title":"Comparative Toxicogenomics database (CTD): update 2023","volume":"51","author":"Davis","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1\u2013related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","article-title":"A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study","volume":"23","author":"Fangusaro","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"W726","DOI":"10.1093\/nar\/gkac297","article-title":"SuperPred 3.0: drug classification and target prediction\u2014a machine learning approach","volume":"50","author":"Gallo","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","article-title":"Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas","volume":"25","author":"Gross","year":"2023","journal-title":"Neuro-Oncology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/neuonc\/noac109","article-title":"Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity","volume":"24","author":"Gross","year":"2022","journal-title":"Neuro-Oncology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1007\/s00415-024-12301-8","article-title":"Efficacy and safety of selumetinib in patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: a systematic review and meta-analysis","volume":"271","author":"Han","year":"2024","journal-title":"J. Neurology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-3-031-12974-2_3","article-title":"ERBB signaling pathway in cancer stem cells","volume":"1393","author":"Hassan","year":"2022","journal-title":"Adv. Exp. Med. Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1200\/JCO.21.00714","article-title":"Selumetinib plus adjuvant radioactive iodine in patients with high-risk differentiated thyroid cancer: a phase III, randomized, placebo-controlled trial (ASTRA)","volume":"40","author":"Ho","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"167904","DOI":"10.1016\/j.scitotenv.2023.167904","article-title":"Efficient analysis of toxicity and mechanisms of environmental pollutants with network toxicology and molecular docking strategy: acetyl tributyl citrate as an example","volume":"905","author":"Huang","year":"2023","journal-title":"Sci. Total Environ."},{"key":"B26","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1212\/wnl.0000000000013296","article-title":"Efficacy and safety of selumetinib in pediatric patients with neurofibromatosis type 1","volume":"98","author":"Hwang","year":"2022","journal-title":"Neurology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40360-023-00681-y","article-title":"Medication overdose data analysis: a review of medication error reports in the FDA adverse event reporting system (FAERS)","volume":"24","author":"Ni","year":"2023","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","article-title":"Management of toxicity to isoform \u03b1-specific PI3K inhibitors","volume":"30","author":"Nunnery","year":"2019","journal-title":"Ann. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s10072-023-06680-5","article-title":"Neurofibromatosis type 1 system-based manifestations and treatments: a review","volume":"44","author":"Saleh","year":"2023","journal-title":"Neurol. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","article-title":"DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)","volume":"50","author":"Sherman","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1.30.1","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards suite: from gene data mining to disease genome sequence analyses","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr. Protoc. Bioinforma."},{"key":"B34","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein\u2013protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"D380","DOI":"10.1093\/nar\/gkv1277","article-title":"STITCH 5: augmenting protein\u2013chemical interaction networks with tissue and affinity data","volume":"44","author":"Szklarczyk","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.kint.2017.11.036","article-title":"Prevention and treatment of hyperphosphatemia in chronic kidney disease","volume":"93","author":"Vervloet","year":"2018","journal-title":"Kidney Int."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-7219-7_1","article-title":"ErbB receptors and cancer","volume":"1652","author":"Wang","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"D1432","DOI":"10.1093\/nar\/gkac1074","article-title":"TOXRIC: a comprehensive database of toxicological data and benchmarks","volume":"51","author":"Wu","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1226086","DOI":"10.3389\/fphar.2023.1226086","article-title":"Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system","volume":"14","author":"Xiong","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"112548","DOI":"10.1016\/j.jep.2020.112548","article-title":"Polyphenols isolated from lychee seed inhibit Alzheimer's disease-associated Tau through improving insulin resistance via the IRS-1\/PI3K\/Akt\/GSK-3\u03b2 pathway","volume":"251","author":"Xiong","year":"2020","journal-title":"J. Ethnopharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"D1180","DOI":"10.1093\/nar\/gkad1004","article-title":"The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods","volume":"52","author":"Zdrazil","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"103305","DOI":"10.1016\/j.critrevonc.2021.103305","article-title":"Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis","volume":"160","author":"Zhao","year":"2021","journal-title":"Crit. Rev. Oncology\/Hematology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"113785","DOI":"10.1016\/j.fct.2023.113785","article-title":"An integrated strategy combining network toxicology and feature-based molecular networking for exploring hepatotoxic constituents and mechanism of Epimedii Folium-induced hepatotoxicity in vitro","volume":"176","author":"Zhao","year":"2023","journal-title":"Food Chem. Toxicol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1432759\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T20:02:54Z","timestamp":1723752174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1432759\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":43,"alternative-id":["10.3389\/fphar.2024.1432759"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1432759","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"article-number":"1432759"}}